

Amendments to the Claims

This listing of claims will replace all prior versions,
and listings of claims in the application:

Listing of Claims:

1 (Previously presented). An isolated peptide
originating from mammalian TNF α cytokines, consisting of a
sequence with more than 80% amino acid identity to SEQ ID NO:5.

Claim 2 (Cancelled).

3 (Previously presented). A peptide according to claim
1, wherein the peptide is the human TNF α cytokine peptide
consisting of the sequence DYLDFAESGQVY (SEQ ID NO:5)

Claims 4-11 (Cancelled).

12 (Previously presented). A derivative of a peptide as
defined in claim 1 by cyclization, stereochemical modification
(use of D series amino acids) or functionalization of one or more
amino acids of said peptide.

13 (Previously presented). An isolated immunogenic
compound comprising: (a) a peptide consisting of a peptide
according to claim 1; and (b) a heterologous carrier protein
that increases the immunogenicity of the peptide in (a).

14 (Previously presented). An immunizing composition,
comprising the immunogenic compound of claim 13 and an adjuvant.

Claims 15 and 16 (Cancelled).

Appln. No. 10/590,905
Amd. dated August 25, 2010
Reply to Office Action of July 20, 2010

17 (Previously presented). A pharmaceutical composition which contains at least one peptide as defined in claim 1 as active ingredient and a pharmaceutically acceptable excipient.

Claim 18-21 (Cancelled).

22 (Previously presented). The derivative of claim 12, wherein the functionalization is acylation.